Lipopolysaccharide (LPS) stimulation of Pancreatic Ductal Adenocarcinoma (PDAC) and macrophages activates the NLRP3 inflammasome that influences the levels of pro-inflammatory cytokines in a co-culture model

Cancer Biol Ther. 2023 Dec 31;24(1):2284857. doi: 10.1080/15384047.2023.2284857. Epub 2023 Nov 29.

Abstract

Modified macrophages, tumor-associated macrophages (TAMs), are key contributors to the survival, growth, and metastatic behavior of pancreatic ductal adenocarcinoma (PDAC) cells. Central to the role of inflammation and TAMs lies the NLRP3 inflammasome. This study investigated the effects of LPS-stimulated inflammation on cell proliferation, levels of pro-inflammatory cytokines, and the NLRP3 inflammasome pathway in a co-culture model using PDAC cells and macrophages in the presence or absence of MCC950, a NLRP3-specific inhibitor. The effects of LPS-stimulated inflammation were tested on two PDAC cell lines (Panc 10.05 and SW 1990) co-cultured with RAW 264.7 macrophages. Cell proliferation was determined using the MTT assay. Levels of pro-inflammatory cytokines, IL-1β, and TNF-α were determined by ELISA. Western blot analyses were used to examine the expression of NLRP3 in both PDAC cells and macrophages. The co-culture and interaction between PDAC cell lines and macrophages led to pro-inflammatory microenvironment under LPS stimulation as evidenced by high levels of secreted IL-1β and TNF-α. Inhibition of the NLRP3 inflammasome by MCC950 counteracted the effects of LPS stimulation on the regulation of the NLRP3 inflammasome and pro-inflammatory cytokines in PDAC and macrophages. However, MCC950 differentially modified the viability of the metastatic vs primary PDAC cell lines. LPS stimulation increased PDAC cell viability by regulating the NLRP3 inflammasome and pro-inflammatory cytokines in the tumor microenvironment of PDAC cells/macrophages co-cultures. The specific inhibition of the NLRP inflammasome by MCC950 effectively counteracted the LPS-stimulated inflammation.

Keywords: LPS-induced inflammation; MCC950; NLRP3 inflammasome; NLRP3 inflammasome inhibitor; Pancreatic ductal adenocarcinoma; tumor associated macrophages.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Pancreatic Ductal* / metabolism
  • Coculture Techniques
  • Cytokines / metabolism
  • Humans
  • Inflammasomes / metabolism
  • Inflammasomes / pharmacology
  • Inflammation / metabolism
  • Lipopolysaccharides / metabolism
  • Lipopolysaccharides / pharmacology
  • Macrophages / metabolism
  • NLR Family, Pyrin Domain-Containing 3 Protein / metabolism
  • Pancreatic Neoplasms* / metabolism
  • Sulfonamides / pharmacology
  • Tumor Microenvironment
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Inflammasomes
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Lipopolysaccharides
  • Cytokines
  • Tumor Necrosis Factor-alpha
  • Sulfonamides

Grants and funding

This work was supported by International Medical University [Project No.: BMS I-2020 (01)].